Menu Search
Equities

Fate Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
F6T:FRA

Fate Therapeutics Inc

Actions
  • Price (EUR)0.8878
  • Today's Change-0.020 / -2.16%
  • Shares traded3.58k
  • 1 Year change-25.83%
  • Beta2.2555
Data delayed at least 15 minutes, as of Feb 11 2026 07:16 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.

  • Revenue in USD (TTM)7.14m
  • Net income in USD-156.09m
  • Incorporated2007
  • Employees181.00
  • Location
    Fate Therapeutics Inc12278 Scripps Summit DriveSAN DIEGO 92131United StatesUSA
  • Phone+1 (858) 875-1803
  • Fax+1 (302) 636-5454
  • Websitehttps://fatetherapeutics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.